Table 1.
Potential indications, antibody doses and estimates of metric ton (MT) requirements (per 1 M Users)
| Target* | Indication | Unmet Need | Assumptions** | Product Requirements/ 1 M Users/Yr (MT) |
|---|---|---|---|---|
| Respiratory Syncytial Virus | Prophylaxis (healthy infants) | 140 M births/yr | 50 mg dose | 0.05 |
| Prophylaxis (adults) | 600 M > 65 years old globally | 10 mg/kg dose | 0.6 | |
| HIV | Therapy | 1.9 M with MDR HIV | Weekly 0.35 g dose | 18.2 |
| 38 M with HIV | ||||
| Prophylaxis (parenteral) | High-risk individuals; difficult to estimate | 2 mAb cocktail at 1 mg/kg each and 3 doses/year | 0.36 | |
| SARS-CoV-2 | Therapy | > 80 M infected; >1.8 M deaths | 2 Abs; 10 mg/kg | 1.2 |
| Prophylaxis | 2 Abs; 1 mg/kg | 0.12 | ||
| Malaria | Prophylaxis | 1.1 B at high risk*** | 5 mg/kg; 3 times per year | 0.9 |
| Influenza | Prophylaxis | High-risk individuals; difficult to estimate | 1–10 mg/kg | 0.06–0.6 |
| Therapy | ~10 M hospitalizations/yr | 1–8 g/dose | 1–8 | |
| Mucosal MPT (HIV, Sperm, HSV) | Prophylaxis | ~140 M (for contraception)**** | 4 Abs (2 HIV Abs, 1 HSV antibody, 1 contraceptive antibody); 50 doses/year X 40 mg total per dose | 2.0 |
MDR = multi-drug resistant; MPT = multipurpose prevention technology.
*emphasis on mAb product concepts that have been through a Phase 1 clinical trial.
**based on a global average weight of 60 kg.
**** Because people are good at estimating their risk for unintended pregnancy but underestimate risk for STI acquisition, contraceptive activity is likely to be a major driver for use of a multipurpose prevention technology (MPT).